Today we welcome OncoLens, a technology company serving cancer care programs, to our portfolio of #healthcare companies. BIP Capital and Atlanta Technology Angels (ATA) led the company’s $1.35 million seed round, which will be deployed to strategically accelerate its growth.
OncoLens’ platform enables a diverse and multispecialty cancer care team to seamlessly collaborate on treatment plans for individual patients. With the explosion of diagnostic tests and treatment options, OncoLens ensures that every complex cancer patient benefits from a discussion by a diverse group of specialists. The company also provides cancer-specific decision support and assists cancer programs to track, discuss and implement nationally approved quality metrics.
As part of this funding round, OncoLens announced Sarath Degala, vice president at BIP Capital, and ATA board member Bill Midgette have joined its board of directors.
“I am very excited to have Bill and Sarath on our board,” said Anju Mathew, OncoLens’ CEO and co-founder. “Their immense experience and knowledge of the healthcare industry will help us serve our customers better as well as expand our product portfolio.”
Degala brings direct operational experience at large health systems where he held multiple C-level positions. “BIP Capital is excited to support OncoLens with this investment, adding another exciting company to our portfolio that improves patients’ lives and increases the efficiency of healthcare,” Degala said.
The investment in OncoLens continues BIP Capital’s strong track record in the healthcare sector, joining current and recently exited portfolio companies that include Excel Health, Prior Authorization Now, Wellview Health and Aspirion Health Resources.